Genmab (GMAB) CFO Anthony Pagano sells 1,100 shares on XCSE

Rhea-AI Filing Summary

Genmab A/S filed a Form 6-K reporting insider share trading by its Executive Vice President & Chief Financial Officer, Anthony Pagano. On February 19, 2026, he executed a sale of 1,100 Genmab shares on Nasdaq Copenhagen at an aggregated price of DKK 1,810.10 per share. Individual trades were carried out at prices between DKK 1,810.00 and DKK 1,811.00. The disclosure is made under Article 19 of the EU Market Abuse Regulation and covers trading by a person discharging managerial responsibilities.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF FEBRUARY 2026

COMMISSION FILE NUMBER 001-38976

Genmab A/S
(Exact name of Registrant as specified in its charter)

Carl Jacobsens Vej 30

2500 Valby

Denmark

+45 70 20 27 28
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F 

This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273, 333-284876 and 333-293505) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit			Description of Exhibit
99.1			Company Announcement Dated February 20, 2026: Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			GENMAB A/S
			BY:			/s/ Anthony Pagano
						Name: Anthony Pagano
						Title: Executive Vice President & Chief Financial Officer

DATE: FEBRUARY 20, 2026

Exhibit 99.1

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement

COPENHAGEN, Denmark; February 20, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.

The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons.

Please find below a statement of such trading in shares issued by Genmab A/S

1.			Details of the person discharging managerial responsibilities / person closely associated
a)			Name			Anthony Pagano
2.			Reason for the notification
a)			Position/status			Executive Vice President & Chief Financial Officer
b)			Initial notification/Amendment			Initial notification
3.			Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)			Name			Genmab A/S
b)			LEI-code			529900MTJPDPE4MHJ122
4.			Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)			Description of the financial instrument, type of instrument Identification code			Share DK0010272202
b)			Nature of the transaction			Sale of shares
c)			Price(s) and volume(s)			Price(s)			Volume(s)
						DKK 1.810,00			899
						DKK 1.810,25			123
						DKK 1.811,00			78
d)			Aggregated information - Aggregated volume - Price			1,100 shares DKK 1,810.10
e)			Date of the transaction			2026-02-19
f)			Place of the transaction			Nasdaq Copenhagen (XCSE)

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby, Denmark Tel: +45 7020 2728
www.genmab.com
Company Announcement no. 07 Page 1/2 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

About Genmab Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.

Contact:    
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs

T: +1 609 524 0065; E: mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations

T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®.

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby, Denmark Tel: +45 7020 2728
www.genmab.com
Company Announcement no. 07 Page 2/2 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122

FAQ

What insider transaction did Genmab (GMAB) disclose in this Form 6-K?

Genmab disclosed a sale of 1,100 shares by its Executive Vice President & Chief Financial Officer, Anthony Pagano. The transaction involved Genmab A/S shares traded on Nasdaq Copenhagen and is reported under Article 19 of the EU Market Abuse Regulation.

At what prices did Genmab CFO Anthony Pagano sell his GMAB shares?

Anthony Pagano sold Genmab shares at prices of DKK 1,810.00, DKK 1,810.25 and DKK 1,811.00. The aggregated transaction data show 1,100 shares sold at an average price of DKK 1,810.10 per share on Nasdaq Copenhagen.

When did the reported insider share sale at Genmab (GMAB) take place?

The insider share sale took place on 2026-02-19. Genmab’s Executive Vice President & Chief Financial Officer, Anthony Pagano, completed the transaction on that date, and the company later published the required notification as a company announcement and Form 6-K.

On which exchange were the Genmab (GMAB) insider transactions executed?

The reported insider trade was executed on Nasdaq Copenhagen (XCSE). The notification specifies that Genmab A/S shares with ISIN DK0010272202 were sold on this marketplace in accordance with European Market Abuse Regulation disclosure rules.

Who is the Genmab (GMAB) insider involved in the reported share sale?

The insider is Anthony Pagano, Genmab’s Executive Vice President & Chief Financial Officer. As a person discharging managerial responsibilities, his trading in Genmab A/S shares must be disclosed publicly under Article 19 of the Market Abuse Regulation.

How many Genmab (GMAB) shares did the CFO sell in the disclosed transaction?

Anthony Pagano sold a total of 1,100 Genmab A/S shares. The filing details the underlying price and volume breakdown and then presents an aggregated figure of 1,100 shares at an average price of DKK 1,810.10 per share.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 35.7 KB